Sign Up
Stories
AEON Biopharma Advances Migraine Treatment
Share
AB Science's Medical Breakthrough Webcas...
ACTICOR BIOTECH Delays Key Documents
ACTICOR BIOTECH: Financial Report Postpo...
4P-Pharma Secures €15 Million Funding
ABBio Innovates Antibody Development
ABIONYX Pharma Files 2023 Document
Overview
API
AEON Biopharma discloses progress on ABP-450 migraine programs, secures $15M in funding through convertible notes.
Ask a question
How might the FDA's alignment for Phase 3 trials impact the future availability of migraine treatments?
In what ways could the $15 million private placement influence AEON Biopharma's research and development efforts?
What potential benefits could ABP-450 bring to patients suffering from chronic migraines compared to existing treatments?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage